|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:drug
|
|
gptkbp:affiliatedWith
|
lincosamide antibiotics
|
|
gptkbp:approvedBy
|
gptkb:FDA
1970 (US)
|
|
gptkbp:ATCCode
|
J01FF01
|
|
gptkbp:availableOn
|
gptkb:butter
capsule
moisturizer
injection
suppository
topical gel
|
|
gptkbp:brand
|
gptkb:Cleocin
gptkb:Dalacin
ClindaMax
|
|
gptkbp:CASNumber
|
18323-44-9
|
|
gptkbp:chemicalFormula
|
C18H33ClN2O5S
|
|
gptkbp:contraindication
|
hypersensitivity to clindamycin
|
|
gptkbp:developedBy
|
gptkb:lincomycin
|
|
gptkbp:discoveredBy
|
gptkb:Upjohn_Company
|
|
gptkbp:discoveredIn
|
1966
|
|
gptkbp:eliminationHalfLife
|
2–3 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clindamycin
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:interactsWith
|
gptkb:erythromycin
neuromuscular blocking agents
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
424.99 g/mol
|
|
gptkbp:notEffectiveAgainst
|
fungal infections
viral infections
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:riskFactor
|
gptkb:pseudomembranous_colitis
|
|
gptkbp:routeOfAdministration
|
oral
topical
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
gptkb:Clostridioides_difficile_infection
nausea
diarrhea
rash
|
|
gptkbp:usedFor
|
acne
pelvic inflammatory disease
bacterial infections
bone infections
malaria (in combination)
|
|
gptkbp:bfsParent
|
gptkb:Streptomyces_species
|
|
gptkbp:bfsLayer
|
6
|